ArQule Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
15,914.00
11,254.00
11,239.00
4,709.00
-
25,764
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
65.00
-
Gross Income
-
-
-
-
65.00
-
SG&A Expense
38,527.00
33,822.00
25,230.00
27,504.00
26,954.00
39,417
EBIT
23,477.00
23,171.00
14,152.00
22,896.00
27,019.00
13,699
Unusual Expense
1,593.00
1,099.00
-
-
902.00
1,552
Non Operating Income/Expense
-
642.00
277.00
-
-
-
Interest Expense
32.00
35.00
-
-
1,520.00
1,666
Pretax Income
24,600.00
23,391.00
13,774.00
22,718.00
29,203.00
15,482
Consolidated Net Income
24,600.00
23,391.00
13,774.00
22,718.00
29,203.00
15,482
Net Income
24,600.00
23,391.00
13,774.00
22,718.00
29,203.00
15,482
Net Income After Extraordinaries
24,600.00
23,391.00
13,774.00
22,718.00
29,203.00
15,482
Net Income Available to Common
24,600.00
23,391.00
13,774.00
22,718.00
29,203.00
15,482
EPS (Basic)
0.39
0.37
0.22
0.33
0.39
0.16
Basic Shares Outstanding
62,480.00
62,627.00
62,808.00
69,714.00
74,813.00
99,035
EPS (Diluted)
0.39
0.37
0.22
0.33
0.39
0.16
Diluted Shares Outstanding
62,480.00
62,627.00
62,808.00
69,714.00
74,813.00
99,035
EBITDA
22,613.00
22,568.00
13,991.00
22,795.00
26,954.00
13,653
Non-Operating Interest Income
502.00
272.00
101.00
178.00
238.00
1,435

About ArQule

View Profile
Address
One Wall Street
Burlington Massachusetts 01803
United States
Employees -
Website http://www.arqule.com
Updated 07/08/2019
ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761.